Vir Biotechnology Inc at H.C. Wainwright & Co LLC 4th Annual Hepatitis B Virus (HBV) Conference (Virtual) Transcript

Oct 25, 2023 / 02:00PM GMT
Patrick Trucchio - H.C. Wainwright & Co. - Analyst

Welcome back everyone to the fourth annual H.C. Wainwright HBV conference. My name is Patrick Trucchio, I'm a senior healthcare analyst at H.C. Wainwright. And it's my pleasure to introduce our next presenter, Phil Pang, CMO of Vir Biotechnology, a commercial stage immunology company focused on combining immunologic insight with cutting-edge technologies to treat and prevent serious infectious diseases.

Questions and Answers:

Patrick Trucchio - H.C. Wainwright & Co. - Analyst

So maybe we can start first with some background on Vir, including founding of the company and what makes this platform unique and differentiated in the area of infectious disease.

Phil Pang - Vir Biotechnology Inc. - EVP, Chief Medical Officer & Interim Head of Research

Thank you, Patrick. Hello to everyone. And again, thank you for this opportunity, Patrick, to speak at this -- at the H.C. Wainwright congress here.

So a little bit about Vir. Vir was founded as an
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot